Literature DB >> 16496355

Sentinel lymph node biopsy in thin melanoma patients.

Dan D Hershko1, Bruce W Robb, Andrew M Lowy, Syed A Ahmad, Go H Ramadas, Debbie A Soldano, Jeffrey J Sussman.   

Abstract

BACKGROUND: We sought to determine the incidence of positive sentinel lymph nodes in thin melanoma (<or=1.0 mm) patients and if subgroups could be identified with a higher risk of occult nodal disease.
METHODS: Patients with <or=1.0 mm lesions treated between 1997 and 2003 were reviewed. Sentinel nodes underwent microscopic analysis including step sectioning and immunohistochemical examination. Some nodes underwent reverse transcriptase-polymerase chain reaction (RT-PCR) evaluation for melanoma markers.
RESULTS: Sixty-four of 107 thin melanoma patients underwent sentinel node biopsy (SNB). Mapped patients were more likely to have Clark >or= III and thicker lesions (mean 0.77 mm vs. 0.47 mm), but were not different in regards to age, sex, or lesion location. Eight percent and 58% of sentinel nodes were positive by routine histology and RT-PCR, respectively. Among mapped patients, younger age was the only significant prognostic factor for node positivity. With a median follow-up of 18 months among all patients, one regional recurrence (at 2 years) has been identified.
CONCLUSIONS: Given the low morbidity of sentinel lymph node biopsy, this procedure should be discussed with selected thin melanoma patients to detect microscopic disease, however PCR positivity by our methods is too commonly seen to be clinically significant in thin melanoma patients and requires additional study. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16496355     DOI: 10.1002/jso.20415

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  6 in total

Review 1.  Surgery and sentinel lymph node biopsy.

Authors:  Mark B Faries; Donald L Morton
Journal:  Semin Oncol       Date:  2007-12       Impact factor: 4.929

2.  Clark level risk stratifies patients with mitogenic thin melanomas for sentinel lymph node biopsy.

Authors:  Edmund K Bartlett; Phyllis A Gimotty; Andrew J Sinnamon; Heather Wachtel; Robert E Roses; Lynn Schuchter; Xiaowei Xu; David E Elder; Michael Ming; Rosalie Elenitsas; DuPont Guerry; Rachel R Kelz; Brian J Czerniecki; Douglas L Fraker; Giorgos C Karakousis
Journal:  Ann Surg Oncol       Date:  2013-10-12       Impact factor: 5.344

3.  Sentinel node biopsy is indicated for thin melanomas ≥0.76 mm.

Authors:  Dale Han; Daohai Yu; Xiuhua Zhao; Suroosh S Marzban; Jane L Messina; Ricardo J Gonzalez; C Wayne Cruse; Amod A Sarnaik; Christopher Puleo; Vernon K Sondak; Jonathan S Zager
Journal:  Ann Surg Oncol       Date:  2012-07-06       Impact factor: 5.344

4.  Importance of sentinel lymph node biopsy in patients with thin melanoma.

Authors:  Byron E Wright; Randall P Scheri; Xing Ye; Mark B Faries; Roderick R Turner; Richard Essner; Donald L Morton
Journal:  Arch Surg       Date:  2008-09

5.  Meta-analysis of sentinel lymph node positivity in thin melanoma (<or=1 mm).

Authors:  Melanie A Warycha; Jan Zakrzewski; Quanhong Ni; Richard L Shapiro; Russell S Berman; Anna C Pavlick; David Polsky; Madhu Mazumdar; Iman Osman
Journal:  Cancer       Date:  2009-02-15       Impact factor: 6.860

6.  Predictive Values of Pathological and Clinical Risk Factors for Positivity of Sentinel Lymph Node Biopsy in Thin Melanoma: A Systematic Review and Meta-Analysis.

Authors:  Hanzi Huang; Ziyao Fu; Jiang Ji; Jiuzuo Huang; Xiao Long
Journal:  Front Oncol       Date:  2022-01-27       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.